» Articles » PMID: 27557501

Identification of Novel Host Biomarkers in Plasma As Candidates for the Immunodiagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Aug 25
PMID 27557501
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

There is an urgent need for new tools for the rapid diagnosis of tuberculosis disease. We evaluated the potentials of 74 host markers as biomarkers for the immunological diagnosis of tuberculosis and monitoring of treatment response. Fifty-five individuals that presented with signs and symptoms requiring investigation for tuberculosis disease were prospectively recruited prior to clinical diagnosis, at a health centre in Cape Town, South Africa. Patients were later classified as having tuberculosis disease or other respiratory diseases (ORD) using a combination of clinical, radiological and laboratory findings. Out of 74 host markers that were evaluated in plasma samples from study participants using a multiplex platform, 18 showed potential as tuberculosis diagnostic candidates with the most promising being NCAM, CRP, SAP, IP-10, ferritin, TPA, I-309, and MIG, which diagnosed tuberculosis disease individually, with area under the ROC curve ≥0.80. Six-marker biosignatures containing NCAM diagnosed tuberculosis disease with a sensitivity of 100% (95%CI, 86.3-100%) and specificity of 89.3% (95%CI, 67.6-97.3%) irrespective of HIV status, and 100% accuracy in the absence of HIV infection. Furthermore, the concentrations of 11 of these proteins changed with treatment, thereby indicating that they may be useful in monitoring of the response to tuberculosis treatment. Our findings have potential to be translated into a point-of-care screening test for tuberculosis, after future validation studies.

Citing Articles

Plasma ferritin, C-reactive protein, and adenosine deaminase levels in tuberculous lymphadenitis and pleuritis and their role in monitoring treatment response.

Nisa Z, Zeshan B, Ambreen A, Mustafa T BMC Infect Dis. 2024; 24(1):1375.

PMID: 39623309 PMC: 11613811. DOI: 10.1186/s12879-024-10228-z.


Candidate serum protein biomarkers for active pulmonary tuberculosis diagnosis in tuberculosis endemic settings.

Ayalew S, Wegayehu T, Wondale B, Tarekegn A, Tessema B, Admasu F BMC Infect Dis. 2024; 24(1):1329.

PMID: 39573991 PMC: 11583743. DOI: 10.1186/s12879-024-10224-3.


Host blood protein biomarkers to screen for tuberculosis disease: a systematic review and meta-analysis.

Gaeddert M, Glaser K, Chendi B, Sultanli A, Koeppel L, MacLean E J Clin Microbiol. 2024; 62(11):e0078624.

PMID: 39445833 PMC: 11559064. DOI: 10.1128/jcm.00786-24.


Persistently high plasma procalcitonin levels despite successful treatment of tuberculous pleuritis and tuberculous lymphadenitis patients.

Nisa Z, Ambreen A, Mustafa T Sci Rep. 2024; 14(1):22590.

PMID: 39343776 PMC: 11439925. DOI: 10.1038/s41598-024-71627-5.


Subtracting the background by reducing cell-free DNA's confounding effects on Mycobacterium tuberculosis quantitation and the sputum microbiome.

Naidoo C, Venter R, Codony F, Agusti G, Kitchin N, Naidoo S Sci Rep. 2024; 14(1):22350.

PMID: 39333362 PMC: 11436789. DOI: 10.1038/s41598-024-73497-3.


References
1.
Sauty A, Colvin R, Wagner L, Rochat S, Spertini F, Luster A . CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol. 2001; 167(12):7084-93. DOI: 10.4049/jimmunol.167.12.7084. View

2.
Kotru M, Rusia U, Sikka M, Chaturvedi S, Jain A . Evaluation of serum ferritin in screening for iron deficiency in tuberculosis. Ann Hematol. 2003; 83(2):95-100. DOI: 10.1007/s00277-003-0788-9. View

3.
Haque N, Fallon J, Taubman M, HARPEL P . The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Blood. 2001; 97(1):39-45. DOI: 10.1182/blood.v97.1.39. View

4.
De Groote M, Nahid P, Jarlsberg L, Johnson J, Weiner M, Muzanyi G . Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One. 2013; 8(4):e61002. PMC: 3630118. DOI: 10.1371/journal.pone.0061002. View

5.
Horne D, Royce S, Gooze L, Narita M, Hopewell P, Nahid P . Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(6):387-94. PMC: 3046810. DOI: 10.1016/S1473-3099(10)70071-2. View